What is Eloxx Pharmaceuticals' stock price target for 2024?

0 analysts have issued 12 month price objectives for Eloxx Pharmaceuticals' stock. Their ELOX share price targets range from $55.00 to $55.00. On average, they predict the company's share price to reach $55.00 in the next year. This suggests a possible upside of 6,766.4% from the stock's current price. View analysts price targets for ELOX or view top-rated stocks among Wall Street analysts .

How have ELOX shares performed in 2024?

Eloxx Pharmaceuticals' stock was trading at $1.20 at the beginning of 2024. Since then, ELOX shares have decreased by 33.3% and is now trading at $0.8010. View the best growth stocks for 2024 here .

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) issued its earnings results on Monday, April, 3rd. The company reported ($2.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.97) by $0.05.

What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO?

1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com . Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ELOX

Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ELOX Stock Alerts

$0.80

-0.14 (-14.88%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.80
▼
$0.98
50-Day Range: $0.75
▼
$1.10
52-Week Range: $0.40
▼
$10.90

Volume: 45,853 shs
Average Volume: 6,575 shs
Market Capitalization: $2.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $55.00

Get Eloxx Pharmaceuticals alerts:

Eloxx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 6,766.4% Upside
$55.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.38
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($7.91) to ($7.39) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.45 out of 5 stars

2.0

Analyst's Opinion

Amount of Analyst Coverage
Eloxx Pharmaceuticals has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for ELOX.

0.0

Dividend Strength

Dividend Yield
Eloxx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eloxx Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELOX.

1.9

News and Social Media Coverage

News Sentiment
Eloxx Pharmaceuticals has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Eloxx Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for ELOX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Eloxx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.20% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($7.91) to ($7.39) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eloxx Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eloxx Pharmaceuticals is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX)

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

ELOX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ELOX Stock News Headlines

April 17, 2024 | finanznachrichten.de

DelveInsight Business Research, LLP: Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

April 17, 2024 | finance.yahoo.com

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 16, 2024 | globenewswire.com

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates

April 5, 2024 | msn.com

Gene therapy and glycoside drugs offer new hope for polycystic kidney disease treatment

March 26, 2024 | markets.businessinsider.com

Nasdaq Inc. Buy Rating: EPS Growth, Valuation Expansion, and Strong FinTech Prospects

March 13, 2024 | finanznachrichten.de

Almirall, S.A.: Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases

March 13, 2024 | globenewswire.com

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 13, 2024 | businesswire.com

Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases

February 22, 2024 | benzinga.com

Eloxx Pharmaceuticals Stock (OTC:ELOX), Short Interest Report

February 16, 2024 | barrons.com

Vertex Pharmaceuticals Inc.

February 6, 2024 | finance.yahoo.com

Eloxx Pharmaceuticals, Inc. (ELOX)

January 30, 2024 | msn.com

CNS Pharmaceuticals prices $4M public offering

December 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Regeneron (REGN)

December 21, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Shockwave Medical (SWAV), Annexon Biosciences (ANNX) and United Therapeutics (UTHR)

December 13, 2023 | finance.yahoo.com

Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor

December 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Lumos Pharma (LUMO), Crispr Therapeutics AG (CRSP) and Biomea Fusion (BMEA)

November 22, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Biomea Fusion (BMEA) and Medtronic (MDT)

November 14, 2023 | msn.com

Hoth stock jumps on positive FDA feedback on drug HT-KIT

November 13, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update

November 8, 2023 | morningstar.com

Eloxx Pharmaceuticals Inc ELOX

October 9, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria

September 21, 2023 | seekingalpha.com

Eloxx Pharmaceuticals prices $2M stock offering

September 19, 2023 | markets.businessinsider.com

Eloxx Pharmaceuticals Announces Registered Direct Offering - Quick Facts

September 19, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

September 18, 2023 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome

See More Headlines

Receive ELOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/03/2023
Today: 4/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ELOX
CUSIP: N/A
CIK: 1035354
Web: www.eloxxpharma.com
Phone: (781) 577-5300
Fax: 908-864-4440
Employees: 18
Year Founded: 2013

Price Target and Rating

Average Stock Price Target: $55.00
High Stock Price Target: $55.00
Low Stock Price Target: $55.00
Potential Upside/Downside: +6,766.4%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($9.07)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,060,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -203.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.24
Quick Ratio: 0.24

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($4.92) per share
Price / Book: -0.16

Miscellaneous

Outstanding Shares: 3,140,000
Free Float: 2,508,000
Market Cap: $2.52 million
Optionable: Not Optionable
Beta: 2.75

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Sumit Aggarwal M.B.A. (Age 51)
President, CEO & Director
Comp: $839.67k
Mr. Daniel E. Geffken M.B.A. (Age 67)
Interim CFO, Principal Financial Officer & Principal Accounting Officer
Comp: $63.96k
Ms. Barbara Ryan
Investor Relations Officer
Dr. Ali Hariri M.D.
Chief Medical Officer

Key Competitors

View All Competitors

ELOX Stock Analysis - Frequently Asked Questions

What is Eloxx Pharmaceuticals' stock price target for 2024?: 0 analysts have issued 12 month price objectives for Eloxx Pharmaceuticals' stock. Their ELOX share price targets range from $55.00 to $55.00. On average, they predict the company's share price to reach $55.00 in the next year. This suggests a possible upside of 6,766.4% from the stock's current price.
View analysts price targets for ELOX or view top-rated stocks among Wall Street analysts.
How have ELOX shares performed in 2024?: Eloxx Pharmaceuticals' stock was trading at $1.20 at the beginning of 2024. Since then, ELOX shares have decreased by 33.3% and is now trading at $0.8010.
View the best growth stocks for 2024 here.
How were Eloxx Pharmaceuticals' earnings last quarter?: Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) issued its earnings results on Monday, April, 3rd. The company reported ($2.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.97) by $0.05.

What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO?: 1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com. Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend.
How do I buy shares of Eloxx Pharmaceuticals?: Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELOX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

Eloxx Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX)

ELOX Stock Price History

ELOX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ELOX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™